Navigation Links
Voices Against Brain Cancer Discusses Recent Finding By Johns Hopkins Researchers Concerning Brain Tumor Treatments
Date:9/28/2013

New York, NY (PRWEB) September 28, 2013

Voices Against Brain Cancer discusses the finding of a repurposed FDA-approved drug that has halted the growth of adult human brain tumor cells in a study conducted by Johns Hopkins researchers.

According to a September 23, 2013 article published by Science Daily titled “Human Brain Tumor Cells Erased in Mice,” Johns Hopkins researchers have found that weeks of treatment with a repurposed FDA-approved drug “halted the growth of – and ultimately left no detectable trace of – human brain tumor cells taken from adult human patients that were implanted into mice.”

The article says scientists targeted a mutation in the IDH1 gene, which was first identified in gliomas by Johns Hopkins cancer researchers back in 2008. The mutation was found in 70 to 80 percent of “lower-grade and progressive forms of the brain cancer.” The team, in collaboration with Johns Hopkins neurosurgeons, obtained tumor cells from human glioma patients that were likely to have IDH1 mutations and injected them under the skin of mice. Once these tumors began to grow, researchers injected the mice with 5-azacytidice for 14 weeks and “saw a dramatic reduction in growth and what appeared to be complete regression.” The tumors still had not regrown seven weeks after the treatment had stopped. Researchers do expect the tumors to regrow and are still monitoring the mice.

Michael Klipper, Chairman of Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, commends the scientists for their endless hard work. “The work being done by these scientists, around the clock, does not go unnoticed. Knowing that this research is going on is extremely comforting to those who have been directly affected by this horrible disease. It leads them to feel hopeful that there will one day be a cure to brain cancer.”

VABC has a wide variety of initiatives in place for brain cancer research, awareness and support. The organization’s research grants fund cutting-edge research programs that will have a monumental impact on the diagnosis and treatment of brain cancer. VABC currently funds research at several esteemed institutions such as Brookhaven National Laboratory, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, John Hopkins, Memorial Sloan-Kettering and Yale, to name a few.

VABC's mission is to find a cure for brain cancer by advancing scientific research, increasing awareness within the medical community and supporting patients, their families and caregivers afflicted with this devastating disease.

For press inquiries, please contact: 5W Public Relations.
#####

Read the full story at http://www.prweb.com/releases/braincancer/vabc/prweb11165704.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Version 2.0 of Award-Winning Proloquo2Go App for iPhone, iPad & iPod touch Speeds Up Communication, Adds New Voices and Customization Options
2. Kentucky Social Security Disability Benefits Lawyer with The Frank Jenkins Law Office Voices Support for Recent Expansion of Compassionate Allowance Program
3. Voices Against Brain Cancer Responds to a Mother’s Successful Fight Against her Glioblastoma
4. Voices Against Brain Cancer Commends a Surgical Innovation That Lights Up Brain Tumors
5. Yakima Traumatic Injury Lawyer Mariano Morales Voices Support for Brain Injury Awareness Month
6. Voices Against Brain Cancer Comments on Link Between Cell Phone Use and Brain Cancer
7. Factoring Receivables & Factoring Invoices Experts Universal Funding Announces Move
8. Voices Against Brain Cancer Commends Andrew Bauer For Raising Awareness About Brain Cancer
9. Voices Against Brain Cancer Responds to Research Identifying Contributing Factor in Brain Tumors
10. Voices Against Brain Cancer Offers Support to Songwriter Battling Brain Cancer
11. Voices Against Brain Cancer Commends Brain Cancer Patient Iram Leon for Winning a Marathon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... TX (PRWEB) , ... October 13, 2017 , ... ... planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, is ... boy fighting to overcome a rare and deadly chromosome abnormality. , After struggling ...
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take ... an inventor from Austin, Texas, has identified a solution. , She developed a prototype ... restricted lighting. As such, it eliminates the need to turn on a light when ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: